Humacyte, Inc.

HUMA Healthcare Biotechnology

Humacyte, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.0 million, up 30.2% from fiscal 2022. In the quarter to June 2026, revenue grew 34.9%, EPS grew 33.3%, free cash flow grew 17.9% and total debt rose 437.5%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

0.43 0.01 −2.27%
Market cap
$122.1M
P/E
0.0×
Fwd P/E
−4.0×
Dividend yield
—
F-score
n/a
Altman Z
−10.48
Beneish M
n/a
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
ROE
(534.42%) (399.51%) 164.78% 114.92%

+8 more TTM periods

ROA
(68.16%) (69.73%) (32.12%) (38.15%)
ROIC
(433.66%) (268.02%) (449.67%) (2,258.85%)
Return on Tangible Assets
(100.37%) (146.96%) (60.08%) (110.43%)
Average Days of Receivables
56.79 78.58 78.98 250.46
Free Cash Flow per Share
(0.42) (0.52) (0.67) (0.67)
Free Cash Flow
(97.56) (102.38) (105.93) (106.40)
Other line items

Show all line items

Columns are period end dates